ES2354824T3 - Pirazolo[1,5-a]pirimidinas útiles como inhibidores de proteínas cinasas. - Google Patents
Pirazolo[1,5-a]pirimidinas útiles como inhibidores de proteínas cinasas. Download PDFInfo
- Publication number
- ES2354824T3 ES2354824T3 ES05816516T ES05816516T ES2354824T3 ES 2354824 T3 ES2354824 T3 ES 2354824T3 ES 05816516 T ES05816516 T ES 05816516T ES 05816516 T ES05816516 T ES 05816516T ES 2354824 T3 ES2354824 T3 ES 2354824T3
- Authority
- ES
- Spain
- Prior art keywords
- inhibitors
- useful
- pirazolo
- pyrimidins
- kinase proteins
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC=CC=C(C(C(N)=N*1=C(C)C2=CC=CC(C(N3COCC3)=O)N2)=C1N)N Chemical compound CC=CC=C(C(C(N)=N*1=C(C)C2=CC=CC(C(N3COCC3)=O)N2)=C1N)N 0.000 description 3
- UTOGPRPIGILDRR-CVCGVWEVSA-O C/C(/C(O)=O)=C\C=C(\C(\C)=[NH+]\C(\N)=C(/C(N)=N)\c1ccc[nH]1)/N Chemical compound C/C(/C(O)=O)=C\C=C(\C(\C)=[NH+]\C(\N)=C(/C(N)=N)\c1ccc[nH]1)/N UTOGPRPIGILDRR-CVCGVWEVSA-O 0.000 description 1
- IWJKKTCNYPQDJK-UHFFFAOYSA-N NC1=NC2=C(c3ccc(C(NCCNI)=O)[nH]3)NC2=C1c1ncccc1 Chemical compound NC1=NC2=C(c3ccc(C(NCCNI)=O)[nH]3)NC2=C1c1ncccc1 IWJKKTCNYPQDJK-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Abstract
Un compuesto de fórmula I': Fórmula a I' o una sal farmacéuticamente aceptable del mismo, en la que R es -(C=Q)R2a, CN, o Y; en la que Y es un anillo de heterociclilo, arilo o heteroarilo, monocíclico o bicíclico, de 5-10 miembros; cada Y está independiente y opcionalmente sustituido con 0-5 JY; Q es O, NH, NR', o S; R' es alquilo C1-6 opcionalmente sustituido con 0-4 apariciones de halo, alifático C1-6, NO2, NH2, -N(alquil C1-6), -N (alquil C1-6)2, SH, -S(alquil C1-6), OH, -O(alquil C1-6), -C(O)(alquil C1- 6), -C(O)NH2, -C(O)N(alquil C1-6), o -C(O)N (alquil C1-6)2; R2a es alifático C1-6, arilo C6-10, heteroarilo de 5-10 miembros, heterociclilo de 5-10 miembros, OR5, o N(R5)2; cada R2a está independiente y opcionalmente sustituido con 0-5 J2a; R1 es H, -C(O)(alquil C1-6), -C(O)O(alquil C1-6), -C(O)NH2, -C(O)N(alquil C1-6), - C(O)N(alquil C1-6)2; o alifático C1-6; cada R1 está opcionalmente sustituido con 0-4 apariciones de halo, haloalquilo C1-6, alifático C1-6, NO2, NH2, -N (alquil C1-6), -N(alquil C1-6)2, SH, -S(alquil C1-6), OH, o -O(alquil C1-6); Z es un enlace o alifático C1-6 en la que hasta dos unidades metileno de la cadena alifática están opcional e independientemente reemplazadas por un heteroátomo seleccionado entre O, N o S, en una disposición químicamente estable; cada R3 y R4 es, independientemente, H, halógeno, alcoxi C1-6, N(R5)2, CN, NO2, o Um-V en la que m es 0 ó 1; V es H, arilo C6-10, heteroarilo de 5-10 miembros, cicloalifático C3-10, heterociclilo de 5-10 miembros, o alifático C1-12 en la que hasta dos unidades metileno de la cadena de alquilideno están opcional e independientemente reemplazadas por un heteroátomo seleccionado entre O, N o S, en una disposición químicamente estable; V está opcionalmente sustituido con 0-4 R8; U es alquilideno de cadena de C1-12 en la que hasta dos unidades metileno de la cadena están opcional e independientemente reemplazadas por -NH-, -NR530 -, -O-, -S-, -CO2-, -OC(O)-, - C(O)CO-, -C(O)-, -C(O)NH-, -C(O)NR5-, -C(=N-CN), -NH-CO-, -NR5CO-, -NHC(O)O-, - NR5C(O)O-, -SO2NH-, -SO2NR5-, -NHSO2-, -NR5SO2-, -NHC(O)NH-, -NR5C(O) NH-, - NHC(O)NR5-, -NR5C(O)NR5, -OC(O)NH-, -OC(O)NR5-, -NHNH-, -NHNR5-, -NR5NR5-, -NR5NH-, -NHSO2NH-, -NR5SO2NH-, -NHSO2NR5-, -NR5SO2NR5-, -SO-, -SO2-, -PO-, -PO2-, o -POR5-; U está opcionalmente sustituido con 0-6 JU; R5 es haloalquilo C1-4, -C(O)COR6, -C(O)R6, -C(O)OR6, -C(O)N(R6)2, -SO2R6, alquil C0-6- heterociclilo, alquil C0-6-heteroarilo, alquil C0-6-arilo, alquil C0-6- cicloalifático o alifático C1-6 en 5 la que hasta tres unidades metileno de la cadena alifática están opcional e independientemente reemplazadas por -NR"-, -O-, -S-, -CO2-, - OC(O)-, -C(O)CO-, -C (O)-, -C(O)NR"-, -NR"CO-, - NR"C(O)O-, -SO2NR"-, -NR"SO2-, -C(O)NR"NR"-, -NR"C(O)NR"-, -OC(O)NR"-, -NR"NR"-, - NR"SO2NR"-, -SO-, -SO2-, -PO-, -PO2-, o -POR"- en una disposición químicamente estable; cada R5 está independiente y opcionalmente sustituido con 0-5 JR5; o dos grupos R5 10 tomados junto con el átomo al que están enlazados, se unen opcionalmente para formar un anillo carbocíclico o heterocíclico de 5-10 miembros; en el que dicho anillo está opcionalmente sustituido con 0-4 J'; R6 es H, alcoxi C1-6, haloalquilo C1-4, alquil C0-6-heterociclilo, alquil C0-6-heteroarilo, alquil C0-6-arilo, alquil C0-6-cicloalifático, o alifático C1-6 en la que hasta dos unidades metileno de la cadena alifática están opcional e independientemente reemplazadas por un heteroátomo seleccionado entre O, N o S, en una disposición químicamente estable; cada R6 está independiente y opcionalmente sustituido con 0-5 JR6; o dos grupos R6 tomados junto con el átomo al que están enlazados, se unen opcionalmente para formar un anillo carbocíclico o heterocíclico de 5-10 miembros; en el que dicho anillo está opcionalmente sustituido con 0-4 J"; R8 es halógeno, haloalquilo C1-4, fenilo, heterociclilo de 5-8 miembros, heteroarilo de 5-6 miembros, -OR6, -N(R6)2, -SR6, NO2, CN, -COOR6, -C(O)N(R6)2, -SO2R6, - SO2N(R6)2, - NR6C(O)R6, -C(O)R6, -OC(O)R6, -NR6C(O)O-R6, -NR6SO2-R6, -C(O)NR6N(R6)2, - NR6C(O)N(R6)2, -OC(O)N(R6)2, -NR6N(R6)2, -NR6SO2N(R6)2 o alifático C1-12, en la que hasta tres unidades metileno de la cadena alifática pueden estar opcionalmente interrumpidas con - C(O)R6, -C(O)O-, -OC(O)-, -C(O)-, -C(O)N(R6)-, -NR6CO(R6)-, -O-, -NR6-, o -S-; cada R8 está independiente y opcionalmente sustituido con 0-5 JR8; cada JY, J2a, Ju, JR5, JR6, JR8, J', y J" se selecciona independientemente entre N(R9)2, SR9, OR9, halo, CN, NO2, COOR9, C(O)R9, SO2R9, SOR9, -X-CF3, -X-SH, -X-OH, haloalquilo C1- 4, arilo C6-10, -X-(arilo C6-10), heteroarilo de 5-10 miembros, -X-(heteroarilo de 5-10 miembros), cicloalifático C3-10, -X-(cicloalifático C3-10), heterociclilo de 5-10 miembros, -X-(heterociclilo de 5- 10 miembros), o X; X es alifático C1-12 en la que hasta dos unidades metileno de la cadena de alquilideno están opcional e independientemente reemplazadas por -NH-, -NR"-, -O-, -S-, -CO2-, -OC(O)-, - C(O)CO-, -C(O)-, -C(O)NH-, -C(O)NR"-, -C(=N-CN), -NHCO-, -NR"CO-, -NHC(O)O-, - NR"C(O)O-, -SO2NH-, -SO2NR"-, -NHSO2-, -NR"SO2- -NHC(O)NH-, -NR"C(O)NH-, - NHC(O)NR"-, -NR"C(O)NR", -OC(O)NH-, -OC(O)NR"-, -NHNH-, -NHNR"-, -NR"NR"-, -NR"NH-, -NHSO2NH-, -NR"SO2NH-, -NHSO2NR"-, -NR"SO2NR"-, -SO-, -SO2-, -PO-, -PO2-, o -POR"-; en una disposición químicamente estable; en las que R" es H o alifático C1-6; cada JY, J2a, Ju, JR5, JR6, J', y J" está opcional e independientemente sustituido con 0-5 4 apariciones de N(R9)2, SR9, OR9, halo, CN, NO2, COOR9, C(O)R9, SO2R9, SOR9, -X-CF3, -X-SH, -X-OH, haloalquilo C1-4, arilo C6-10, -X-(arilo C6-10), heteroarilo de 5-10 miembros, -X-(heteroarilo de 5-10 miembros), cicloalifático C3-10, -X-(cicloalifático C3-10), heterociclilo de 5-10 miembros, - X-(heterociclilo de 5-10 miembros), o X; R9 es H, alifático C1-6, haloalquilo C1-4, arilo C6-10, -X-(arilo C6-10), heteroarilo de 5-10 miembros, -X-(heteroarilo de 5-10 miembros), cicloalifático C3-10, -X-(cicloalifático C3-10), heterociclilo de 5-10 miembros, -X-(heterociclilo de 5-10 miembros) o X, o en las que dos R9, tomados junto con el átomo al que están unidos, forman un heterociclilo de 5-10 miembros, en la que dicho heterociclilo está opcionalmente sustituido con 0-4 apariciones de halo, CN, NO2, - COOH, -COO(alquil C1-6), -C(O)H, SO2H, SO2(alquil C1-6), haloalifático C1-6, NH2, -NH(alquil C1- 6), -N (alquil C1-6)2 , SH, -S(alquil C1-6) , OH, - O(alquil C1-6), -C(O)(alquil C1-6), -C(O)NH2, - C(O)NH(alquil C1-6), -C(O)N(alquil C1-6)2, -C(O)NH2, -C(O)NH(alquil C1-6), o -C(O)N(alquil C1-6)2, haloalquilo C1-4, arilo C6-10, -X-(arilo C6-10), heteroarilo de 5-10 miembros, -X-(heteroarilo de 5-10 miembros), cicloalifático C3-10, -X-(cicloalifático C3-10), heterociclilo de 5-10 miembros, -X- (heterociclilo de 5-10 miembros), o X, con lo que se excluyen los siguientes compuestos: - 3-(2-amino-5-metil-pirazolo[1,5-a]pirimidin-3-il)azo-4,6- dimetiltieno[2,3-b]piridina, - 5-fenil-3-fenilazo-pirazolo[1,5-a]pirimidin-2-ilamina.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62544604P | 2004-11-04 | 2004-11-04 | |
US625446P | 2004-11-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2354824T3 true ES2354824T3 (es) | 2011-03-18 |
Family
ID=35809833
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES05816516T Active ES2354824T3 (es) | 2004-11-04 | 2005-11-04 | Pirazolo[1,5-a]pirimidinas útiles como inhibidores de proteínas cinasas. |
Country Status (21)
Country | Link |
---|---|
US (1) | US7528138B2 (es) |
EP (1) | EP1812440B1 (es) |
JP (2) | JP5030229B2 (es) |
KR (1) | KR20070090172A (es) |
CN (1) | CN101094853B (es) |
AT (1) | ATE482213T1 (es) |
AU (1) | AU2005304784B2 (es) |
CA (1) | CA2586375A1 (es) |
DE (1) | DE602005023763D1 (es) |
DK (1) | DK1812440T3 (es) |
ES (1) | ES2354824T3 (es) |
HK (1) | HK1113569A1 (es) |
IL (1) | IL182893A0 (es) |
MX (1) | MX337817B (es) |
NO (1) | NO20072795L (es) |
NZ (1) | NZ555236A (es) |
PT (1) | PT1812440E (es) |
RU (1) | RU2417996C2 (es) |
SI (1) | SI1812440T1 (es) |
WO (1) | WO2006052913A1 (es) |
ZA (1) | ZA200704476B (es) |
Families Citing this family (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0104140D0 (sv) * | 2001-12-07 | 2001-12-07 | Astrazeneca Ab | Novel Compounds |
NZ555236A (en) * | 2004-11-04 | 2010-10-29 | Vertex Pharma | Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases |
DK1853588T3 (da) * | 2005-02-16 | 2008-09-15 | Astrazeneca Ab | Kemiske forbindelser |
US20090156617A1 (en) * | 2005-05-12 | 2009-06-18 | Northrup Alan B | Tyrosine kinase inhibitors |
BRPI0610184A2 (pt) * | 2005-05-16 | 2012-09-25 | Astrazeneca Ab | composto, sal farmaceuticamente aceitável de um composto, processo para preparar um composto ou um sal farmaceuticamente aceitável do mesmo, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, métodos para a inibição da atividade de trk, para o tratamento ou profilaxia de cáncer e para a produção de um efeito anti-proliferativo em um animal de sanque quente, e, composição farmacêutica |
WO2007046867A2 (en) * | 2005-05-19 | 2007-04-26 | Xenon Pharmaceuticals Inc. | Piperidine derivatives and their uses as therapeutic agents |
JP2008545660A (ja) * | 2005-05-20 | 2008-12-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼ阻害剤として有用なピロロピリジン化合物 |
CA2626375A1 (en) * | 2005-10-28 | 2007-05-03 | Astrazeneca Ab | 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer |
CN103214484B (zh) | 2005-12-13 | 2016-07-06 | 因塞特控股公司 | 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡啶和吡咯并[2,3-b]嘧啶 |
GB0601638D0 (en) * | 2006-01-27 | 2006-03-08 | Merck Sharp & Dohme | Therapeutic treatment |
US8198448B2 (en) | 2006-07-14 | 2012-06-12 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
PE20080403A1 (es) | 2006-07-14 | 2008-04-25 | Amgen Inc | Derivados heterociclicos fusionados y metodos de uso |
US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
WO2008054827A2 (en) * | 2006-11-03 | 2008-05-08 | Pharmacyclics, Inc. | Bruton's tyrosine kinase activity probe and method of using |
EP2144878A2 (en) * | 2007-03-22 | 2010-01-20 | Vertex Pharmaceuticals Incorporated | N-heterocyclic compounds useful as inhibitors of janus kinases |
JP2010524911A (ja) * | 2007-04-18 | 2010-07-22 | アストラゼネカ アクチボラグ | 5−アミノピラゾール−3−イル−3H−イミダゾ[4,5−b]ピリジン誘導体と癌の治療のためのその使用 |
WO2008135786A1 (en) * | 2007-05-04 | 2008-11-13 | Astrazeneca Ab | Amino-thiazolyl- pyrimidine derivatives and their use for the treatment of cancer |
UA99459C2 (en) * | 2007-05-04 | 2012-08-27 | Астразенека Аб | 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer |
EP2740731B1 (en) | 2007-06-13 | 2016-03-23 | Incyte Holdings Corporation | Crystalline salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
CN101878217B (zh) | 2007-09-28 | 2014-01-15 | 协和发酵麒麟株式会社 | 皮肤疾病的预防和/或治疗剂 |
EA020777B1 (ru) * | 2007-11-16 | 2015-01-30 | Инсайт Корпорейшн | 4-пиразолил-n-арилпиримидин-2-амины, 4-пиразолил-n-пиразолилпиримидин-2-амины и 4-пиразолил-n-пиридилпиримидин-2-амины в качестве ингибиторов киназ janus |
JP5520831B2 (ja) * | 2007-12-19 | 2014-06-11 | アムジエン・インコーポレーテツド | Pi3キナーゼの阻害薬 |
MX2010006748A (es) | 2007-12-19 | 2010-08-18 | Vertex Pharma | Pirazolo[1,5-a]pirimidinas utiles como inhibidores de jak2. |
JP5638961B2 (ja) | 2008-03-13 | 2014-12-10 | ザ ジェネラル ホスピタル コーポレイション | Bmpシグナル伝達経路のインヒビター |
BRPI0915101A2 (pt) * | 2008-06-11 | 2017-03-21 | Astrazeneca Ab | composto, uso do mesmo, método para tratar câncer em um animal de sangue quente, composição farmacêutica, e, processo para preparar um composto |
JP5746032B2 (ja) * | 2008-09-19 | 2015-07-08 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | 3,4−ジヒドロ−2H−ピロロ[1,2−a]ピラジン−1−オン誘導体 |
RS53350B (en) | 2008-09-22 | 2014-10-31 | Array Biopharma, Inc. | SUBSTITUTED COMPOUNDS OF IMIDASO [1,2-B] PYRIDASINE AS INK KINASE INHIBITORS |
CA2737217A1 (en) * | 2008-09-30 | 2010-04-08 | Astrazeneca Ab | Heterocyclic jak kinase inhibitors |
AU2009308675A1 (en) * | 2008-10-31 | 2010-05-06 | Genentech, Inc. | Pyrazolopyrimidine JAK inhibitor compounds and methods |
GB0821913D0 (en) | 2008-12-02 | 2009-01-07 | Price & Co | Antibacterial compounds |
US8716303B2 (en) | 2009-05-22 | 2014-05-06 | Incyte Corporation | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
HUE046493T2 (hu) | 2009-05-22 | 2020-03-30 | Incyte Holdings Corp | 3-[4-(7H-Pirrolo[2,3-d]pirimidin-4-il)-lH-pirazol-l-il]oktán- vagy heptán-nitril JAK inhibitorokként |
CA2762479A1 (en) * | 2009-05-28 | 2010-12-02 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-met protein kinase |
TWI574963B (zh) | 2009-06-17 | 2017-03-21 | 維泰克斯製藥公司 | 流感病毒複製之抑制劑 |
UA110324C2 (en) | 2009-07-02 | 2015-12-25 | Genentech Inc | Jak inhibitory compounds based on pyrazolo pyrimidine |
AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
TW201113285A (en) * | 2009-09-01 | 2011-04-16 | Incyte Corp | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
PL2473049T3 (pl) | 2009-09-04 | 2019-07-31 | Biogen Ma Inc. | Inhibitory kinazy tyrozynowej brutona |
MY175156A (en) | 2010-03-10 | 2020-06-11 | Incyte Corp | Piperidin-4-yl azetidine derivatives as jak1 inhibitors |
WO2011130515A1 (en) * | 2010-04-14 | 2011-10-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Arylthiazolyl piperidines and related compounds as modulators of survival motor neuron (smn) protein production |
NZ703111A (en) | 2010-05-17 | 2016-07-29 | Incozen Therapeutics Pvt Ltd | Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases |
PL3205654T3 (pl) | 2010-05-20 | 2019-08-30 | Array Biopharma, Inc. | Związki makrocykliczne jako inhibitory kinazy TRK |
TWI499421B (zh) | 2010-05-21 | 2015-09-11 | Incyte Corp | Jak抑制劑的局部製劑 |
GB2480814A (en) * | 2010-06-01 | 2011-12-07 | Summit Corp Plc | Compounds for the treatment of clostridium difficile-associated disease |
CA2801274C (en) | 2010-06-01 | 2021-06-15 | Summit Corporation Plc | Compounds for the treatment of clostridium difficile-associated disease |
CN103415515B (zh) | 2010-11-19 | 2015-08-26 | 因塞特公司 | 作为jak抑制剂的环丁基取代的吡咯并吡啶和吡咯并嘧啶衍生物 |
JP5917544B2 (ja) | 2010-11-19 | 2016-05-18 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Jak阻害剤としての複素環置換ピロロピリジンおよびピロロピリミジン |
RU2013132681A (ru) * | 2010-12-16 | 2015-01-27 | Вертекс Фармасьютикалз Инкорпорейтед | Ингибиторы репликации вирусов гриппа |
US9073947B2 (en) * | 2011-06-10 | 2015-07-07 | Merck Patent Gmbh | Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity |
AU2012273164B2 (en) | 2011-06-20 | 2015-05-28 | Incyte Holdings Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors |
WO2012178125A1 (en) | 2011-06-22 | 2012-12-27 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
UA118010C2 (uk) | 2011-08-01 | 2018-11-12 | Вертекс Фармасьютікалз Інкорпорейтед | Інгібітори реплікації вірусів грипу |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
US9096605B2 (en) * | 2011-08-24 | 2015-08-04 | Glaxosmithkline Llc | Pyrazolopyrimidine derivatives as PI3 kinase inhibitors |
UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
JP6192708B2 (ja) | 2012-03-30 | 2017-09-06 | ライゼン・ファーマシューティカルズ・エスアー | C−metプロテインキナーゼ調節物質としての新規3,5−二置換−3h−イミダゾ[4,5−b]ピリジン化合物および3,5−二置換−3h−[1,2,3]トリアゾロ[4,5−b]ピリジン化合物 |
US9193733B2 (en) | 2012-05-18 | 2015-11-24 | Incyte Holdings Corporation | Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
AR091273A1 (es) | 2012-06-08 | 2015-01-21 | Biogen Idec Inc | Inhibidores de pirimidinil tirosina quinasa |
CA2882132C (en) * | 2012-08-16 | 2021-07-06 | The Scripps Research Institute | Kappa opioid ligands |
WO2014078486A1 (en) | 2012-11-15 | 2014-05-22 | Incyte Corporation | Sustained-release dosage forms of ruxolitinib |
WO2014081996A1 (en) * | 2012-11-23 | 2014-05-30 | Glaxosmithkline Llc | Novel compounds as diacylglycerol acyltransferase inhibitors |
NZ731337A (en) | 2012-12-07 | 2019-02-22 | Vertex Pharma | Compounds useful as inhibitors of atr kinase |
TW201501713A (zh) * | 2013-03-01 | 2015-01-16 | Kyowa Hakko Kirin Co Ltd | 眼炎症性疾病之預防及/或治療劑 |
ES2707355T3 (es) | 2013-03-06 | 2019-04-03 | Incyte Holdings Corp | Procesos y productos intermedios para elaborar un inhibidor de JAK |
EP2970311A4 (en) * | 2013-03-14 | 2016-11-23 | Brigham & Womens Hospital | BMP INHIBITORS AND METHODS OF USE |
WO2014143242A1 (en) * | 2013-03-15 | 2014-09-18 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
JP2016512815A (ja) | 2013-03-15 | 2016-05-09 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Atrキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体 |
JP2016512239A (ja) | 2013-03-15 | 2016-04-25 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Atrキナーゼの阻害剤として有用な化合物 |
WO2014175370A1 (ja) * | 2013-04-25 | 2014-10-30 | 塩野義製薬株式会社 | ピロリジン誘導体およびそれらを含有する医薬組成物 |
CA3155500A1 (en) | 2013-08-07 | 2015-02-12 | Incyte Corporation | Sustained release dosage forms for a jak1 inhibitor |
SI3421468T1 (sl) | 2013-11-13 | 2021-03-31 | Vertex Pharmaceuticals Incorporated | Postopki za pripravo inhibitorjev replikacije virusov influence |
ES2741444T3 (es) | 2013-11-13 | 2020-02-11 | Vertex Pharma | Inhibidores de la replicación de virus de la gripe |
WO2015073267A1 (en) * | 2013-11-15 | 2015-05-21 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
CN104650092B (zh) * | 2013-11-16 | 2017-11-10 | 广东东阳光药业有限公司 | 取代的杂芳基化合物及其组合物和用途 |
PL3077397T3 (pl) | 2013-12-06 | 2020-04-30 | Vertex Pharmaceuticals Inc. | Związek 2-amino-6-fluoro-n-[5-fluoro-pirydyn-3-ylo]pyrazolo [1,5-a]pirymidino-3-karboksamidu przydatny jako inhibitor kinazy atr, jego wytwarzanie, różne postacie stałe i ich radioznakowane pochodne |
US9346815B2 (en) | 2014-05-23 | 2016-05-24 | Genentech, Inc. | 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds, compositions and methods of use thereof |
WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
SI3152212T1 (sl) | 2014-06-05 | 2020-06-30 | Vertex Pharmaceuticals Inc. | Radioaktivno označeni derivati 2-amino-6-fluoro-N-(5-fluoro-piridin-3-IL)-pirazolo (1,5-A)pirimidin-3- karboksamidne spojine, koristni kot inhibitor kinaze ATR, priprava navedene spojine in njene različne trdne oblike |
RS59054B1 (sr) | 2014-06-17 | 2019-08-30 | Vertex Pharma | Postupak za lečenje raka korišćenjem kombinacije chk1 i atr inhibitora |
WO2016011019A1 (en) | 2014-07-15 | 2016-01-21 | The Brigham And Women's Hospital, Inc. | Compositions and methods for inhibiting bmp |
UA123044C2 (uk) | 2014-11-16 | 2021-02-10 | Ерей Біофарма Інк. | КРИСТАЛІЧНА ФОРМА (S)-N-(5-((R)-2-(2,5-ДИФТОРФЕНІЛ)-ПІРОЛІДИН-1-ІЛ)-ПІРАЗОЛО[1,5-a]ПІРИМІДИН-3-ІЛ)-3-ГІДРОКСИПІРОЛІДИН-1-КАРБОКСАМІД ГІДРОСУЛЬФАТУ |
WO2016183116A1 (en) | 2015-05-13 | 2016-11-17 | Vertex Pharmaceuticals Incorporated | Methods of preparing inhibitors of influenza viruses replication |
MA42422A (fr) | 2015-05-13 | 2018-05-23 | Vertex Pharma | Inhibiteurs de la réplication des virus de la grippe |
AU2016331955B2 (en) | 2015-09-30 | 2022-07-21 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors |
EP3368039A1 (en) | 2015-10-26 | 2018-09-05 | The Regents of The University of Colorado, A Body Corporate | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
BR112018070304A2 (pt) | 2016-04-04 | 2019-01-29 | Loxo Oncology Inc | formulações líquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida |
US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
BR112018073504A2 (pt) | 2016-05-18 | 2019-03-26 | Array Biopharma, Inc. | processo para preparar (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)-pirazol[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida e sais da mesma |
FI3484888T5 (fi) | 2016-07-18 | 2024-02-26 | Univ Health Network | Ttk:n estäjän kiinteitä muotoja |
KR20190035769A (ko) | 2016-07-21 | 2019-04-03 | 바이오젠 엠에이 인코포레이티드 | 브루톤 타이로신 카이나제 저해제의 석신에이트 형태 및 조성물 |
JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
EP3615538B1 (en) | 2017-04-27 | 2024-02-07 | The Brigham and Women's Hospital, Inc. | Novel alk2 inhibitors and methods for inhibiting bmp signaling |
PL233595B1 (pl) * | 2017-05-12 | 2019-11-29 | Celon Pharma Spolka Akcyjna | Pochodne pirazolo[1,5-a]pirymidyny jako inhibitory kinazy JAK |
RU2769696C2 (ru) | 2017-05-22 | 2022-04-05 | Ф. Хоффманн-Ля Рош Аг | Терапевтические соединения и композиции и способы их применения |
AR113922A1 (es) | 2017-12-08 | 2020-07-01 | Incyte Corp | Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas |
TWI816742B (zh) * | 2018-01-29 | 2023-10-01 | 美商維泰克斯製藥公司 | Gcn2抑制劑及其用途 |
MA51771B1 (fr) | 2018-01-30 | 2022-03-31 | Incyte Corp | Procédés de préparation de (1-(3-fluoro-2-(trifluorométhyl)isonicotinyl)pipéridine-4-one) |
PE20210402A1 (es) | 2018-03-30 | 2021-03-02 | Incyte Corp | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak |
JP2022512824A (ja) * | 2018-10-26 | 2022-02-07 | ケロス セラピューティクス インコーポレイテッド | Alk2阻害剤の結晶形 |
TW202039502A (zh) | 2018-12-20 | 2020-11-01 | 美商英塞特公司 | 咪唑并嗒嗪及咪唑并吡啶化合物及其用途 |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002501532A (ja) * | 1997-05-30 | 2002-01-15 | メルク エンド カンパニー インコーポレーテッド | 新規血管形成阻害薬 |
US6245759B1 (en) * | 1999-03-11 | 2001-06-12 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
GB0103926D0 (en) * | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
US7550470B2 (en) * | 2002-12-11 | 2009-06-23 | Merck & Co. Inc. | Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors |
NZ555236A (en) * | 2004-11-04 | 2010-10-29 | Vertex Pharma | Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases |
-
2005
- 2005-11-04 NZ NZ555236A patent/NZ555236A/en not_active IP Right Cessation
- 2005-11-04 CA CA002586375A patent/CA2586375A1/en not_active Abandoned
- 2005-11-04 SI SI200531195T patent/SI1812440T1/sl unknown
- 2005-11-04 CN CN2005800450252A patent/CN101094853B/zh not_active Expired - Fee Related
- 2005-11-04 PT PT05816516T patent/PT1812440E/pt unknown
- 2005-11-04 JP JP2007540144A patent/JP5030229B2/ja not_active Expired - Fee Related
- 2005-11-04 AT AT05816516T patent/ATE482213T1/de active
- 2005-11-04 MX MX2007005439A patent/MX337817B/es active IP Right Grant
- 2005-11-04 WO PCT/US2005/040344 patent/WO2006052913A1/en active Application Filing
- 2005-11-04 ES ES05816516T patent/ES2354824T3/es active Active
- 2005-11-04 RU RU2007120518/04A patent/RU2417996C2/ru not_active IP Right Cessation
- 2005-11-04 AU AU2005304784A patent/AU2005304784B2/en not_active Ceased
- 2005-11-04 EP EP05816516A patent/EP1812440B1/en active Active
- 2005-11-04 KR KR1020077012308A patent/KR20070090172A/ko not_active Application Discontinuation
- 2005-11-04 ZA ZA200704476A patent/ZA200704476B/xx unknown
- 2005-11-04 DE DE602005023763T patent/DE602005023763D1/de active Active
- 2005-11-04 DK DK05816516.8T patent/DK1812440T3/da active
- 2005-11-04 US US11/266,935 patent/US7528138B2/en not_active Expired - Fee Related
-
2007
- 2007-05-01 IL IL182893A patent/IL182893A0/en unknown
- 2007-06-01 NO NO20072795A patent/NO20072795L/no not_active Application Discontinuation
-
2008
- 2008-03-13 HK HK08102917.8A patent/HK1113569A1/xx not_active IP Right Cessation
- 2008-10-29 JP JP2008278235A patent/JP2009067803A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
SI1812440T1 (sl) | 2011-04-29 |
NZ555236A (en) | 2010-10-29 |
KR20070090172A (ko) | 2007-09-05 |
AU2005304784B2 (en) | 2011-03-24 |
US7528138B2 (en) | 2009-05-05 |
RU2007120518A (ru) | 2008-12-10 |
AU2005304784A1 (en) | 2006-05-18 |
CA2586375A1 (en) | 2006-05-18 |
CN101094853B (zh) | 2011-07-13 |
MX2007005439A (es) | 2008-02-19 |
WO2006052913A1 (en) | 2006-05-18 |
PT1812440E (pt) | 2011-01-25 |
CN101094853A (zh) | 2007-12-26 |
US20060135537A1 (en) | 2006-06-22 |
JP2008519059A (ja) | 2008-06-05 |
EP1812440A1 (en) | 2007-08-01 |
JP5030229B2 (ja) | 2012-09-19 |
EP1812440B1 (en) | 2010-09-22 |
NO20072795L (no) | 2007-06-01 |
JP2009067803A (ja) | 2009-04-02 |
DE602005023763D1 (de) | 2010-11-04 |
HK1113569A1 (en) | 2008-10-10 |
ATE482213T1 (de) | 2010-10-15 |
DK1812440T3 (da) | 2011-01-31 |
IL182893A0 (en) | 2007-08-19 |
MX337817B (es) | 2011-11-04 |
ZA200704476B (en) | 2008-09-25 |
RU2417996C2 (ru) | 2011-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2354824T3 (es) | Pirazolo[1,5-a]pirimidinas útiles como inhibidores de proteínas cinasas. | |
ZA200707342B (en) | Pyrrolopyrimidines useful as inhibitors of protein kinase | |
HK1096673A1 (en) | Compositions useful as inhibitors of protein kinases | |
TW200633980A (en) | Pyridones useful as inhibitors of kinases | |
SG166828A1 (en) | Aminopyrimidines useful as kinase inhibitors | |
ATE450530T1 (de) | Zusammensetzungen zur verwendung als protein- kinase-inhibitoren | |
MX2009006700A (es) | Derivados de 5-ciano-4-(pirolo)[2,3b]piridina-3-il)-pirimidinas utiles como inhibidores de proteina-cinasas. | |
ATE542814T1 (de) | Pyrazinkinaseinhibitoren | |
ATE466580T1 (de) | Azolylaminoazine als proteinkinasehemmer | |
ATE468336T1 (de) | Azolylaminoazine als proteinkinasehemmer | |
ATE365733T1 (de) | Zusammensetzungen brauchbar als protein-kinase- inhibitoren | |
UA84930C2 (ru) | Пиррольные соединения как ингибиторы протеинкиназ erk, их синтез и соответствующие промежуточные соединения | |
DE602007007985D1 (de) | Als inhibitoren von proteinkinasen geeignete aminopyrimidine | |
SG151327A1 (en) | Deazapurines useful as inhibitors of janus kinases | |
DE602004014117D1 (de) | Thiazole zur verwendung als inhibitoren von protein-kinasen | |
CY1112253T1 (el) | Ενωσεις διαμινοτριαζολιου χρησιμες ως αναστολεις κινασης πρωτεϊνης | |
MX2009006345A (es) | Compuestos utiles como inhibidores de proteina cinasa. | |
IL179206A0 (en) | Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same | |
ATE389651T1 (de) | Als inhibitoren von c-met geeignete pyrrolzusammensetzungen | |
MX2009005231A (es) | Composiciones utiles como inhibidores de proteina cinasa. |